{"id":"jab-21822","safety":{"commonSideEffects":[{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL5095185","moleculeType":"Small molecule","molecularWeight":"476.55"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"JAB-21822 targets FGFR pathways implicated in various cancers and fibrotic diseases. By inhibiting FGFR kinase activity, the drug suppresses downstream signaling cascades that drive cell proliferation and survival in FGFR-dependent tumors and tissues. This mechanism is particularly relevant in cancers with FGFR amplifications, fusions, or mutations.","oneSentence":"JAB-21822 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:17:32.905Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"FGFR-driven solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT05194995","phase":"PHASE1, PHASE2","title":"JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2022-02-17","conditions":"Advanced Colorectal Cancer, Small Intestinal Cancer, Appendiceal Cancer","enrollment":48},{"nctId":"NCT05009329","phase":"PHASE1, PHASE2","title":"A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China","status":"ACTIVE_NOT_RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2021-07-26","conditions":"NSCLC, Solid Tumor","enrollment":315},{"nctId":"NCT06008288","phase":"PHASE2","title":"A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2023-10-27","conditions":"KRAS P.G12C, Pancreatic Cancer, Solid Tumor","enrollment":88},{"nctId":"NCT07339839","phase":"PHASE1, PHASE2","title":"Glecirasib Combined With Ivonescimab for First-line Treatment of KRAS G12C-mutated NSCLC","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2026-03-01","conditions":"NSCLC Stage IV, KRAS G12C","enrollment":42},{"nctId":"NCT05002270","phase":"PHASE1, PHASE2","title":"JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation","status":"COMPLETED","sponsor":"Jacobio Pharmaceuticals Co., Ltd.","startDate":"2021-09-03","conditions":"Advanced Solid Tumor, NSCLC, CRC","enrollment":29},{"nctId":"NCT06838338","phase":"PHASE1","title":"JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jian Li","startDate":"2025-03-20","conditions":"Colorectal Cancer","enrollment":30},{"nctId":"NCT05875493","phase":"PHASE1","title":"A Food Effect Study of JAB-21822 in Healthy Subjects","status":"COMPLETED","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2023-05-12","conditions":"Food Effect in Healthy Participants","enrollment":18},{"nctId":"NCT05288205","phase":"PHASE1, PHASE2","title":"Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2022-04-14","conditions":"KRAS P.G12C, Non-small Cell Lung Cancer, Colorectal Cancer","enrollment":240},{"nctId":"NCT06416410","phase":"PHASE3","title":"JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2024-08-07","conditions":"Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer","enrollment":392},{"nctId":"NCT05920941","phase":"PHASE1","title":"Mass Balance Study of [14C]JAB-21822","status":"COMPLETED","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2023-07-08","conditions":"Mass Balance Study in Healthy Subjects","enrollment":6},{"nctId":"NCT06162169","phase":"PHASE1","title":"A Clinical Trial to Evaluate JAB-21822 Drug-drug Interactions in Healthy Subjects","status":"COMPLETED","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2023-11-25","conditions":"Healthy Subjects","enrollment":66},{"nctId":"NCT05276726","phase":"PHASE1, PHASE2","title":"A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1","status":"RECRUITING","sponsor":"Allist Pharmaceuticals, Inc.","startDate":"2022-08-17","conditions":"Non-small Cell Lung Cancer","enrollment":104},{"nctId":"NCT06563999","phase":"PHASE2","title":"Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2024-11-01","conditions":"Lung Cancer Stage III, Mutation","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["glecirasib","Glecirasib"],"phase":"phase_3","status":"active","brandName":"JAB-21822","genericName":"JAB-21822","companyName":"Allist Pharmaceuticals, Inc.","companyId":"allist-pharmaceuticals-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"JAB-21822 is a selective inhibitor of fibroblast growth factor receptor (FGFR) signaling that blocks aberrant growth signals in cells dependent on FGFR activation. Used for FGFR-driven solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}